Investment Analysts’ Weekly Ratings Updates for Globus Medical (GMED)

A number of firms have modified their ratings and price targets on shares of Globus Medical (NYSE: GMED) recently:

  • 1/10/2018 – Globus Medical was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 1/10/2018 – Globus Medical had its “sell” rating reaffirmed by analysts at Barclays PLC. They now have a $36.00 price target on the stock.
  • 1/10/2018 – Globus Medical had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $51.00 price target on the stock, up previously from $46.00.
  • 1/4/2018 – Globus Medical was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
  • 1/2/2018 – Globus Medical was given a new $45.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
  • 1/2/2018 – Globus Medical was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $48.00 price target on the stock.
  • 12/4/2017 – Globus Medical was upgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “outperform” rating. They now have a $46.00 price target on the stock.
  • 12/1/2017 – Globus Medical was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/20/2017 – Globus Medical was given a new $42.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.

Shares of Globus Medical Inc (GMED) traded up $0.31 during midday trading on Thursday, reaching $43.28. 1,217,600 shares of the company’s stock traded hands, compared to its average volume of 888,582. The company has a market capitalization of $4,150.00, a P/E ratio of 39.35, a P/E/G ratio of 2.66 and a beta of 0.56. Globus Medical Inc has a twelve month low of $25.67 and a twelve month high of $46.51.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Wednesday, November 8th. The medical device company reported $0.30 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.30. The business had revenue of $151.74 million during the quarter, compared to the consensus estimate of $150.73 million. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. equities research analysts predict that Globus Medical Inc will post 1.27 EPS for the current year.

In other news, insider A Brett Murphy sold 51,449 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the transaction, the insider now directly owns 49,768 shares of the company’s stock, valued at $1,741,880. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Steven Payne sold 3,076 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $39.30, for a total transaction of $120,886.80. Following the transaction, the chief accounting officer now directly owns 23,847 shares in the company, valued at $937,187.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,908 shares of company stock worth $4,747,975. Corporate insiders own 28.21% of the company’s stock.

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply